{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T01:17:13Z","timestamp":1773278233040,"version":"3.50.1"},"reference-count":80,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2011,5,1]],"date-time":"2011-05-01T00:00:00Z","timestamp":1304208000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Trends in Molecular Medicine"],"published-print":{"date-parts":[[2011,5]]},"DOI":"10.1016\/j.molmed.2011.01.002","type":"journal-article","created":{"date-parts":[[2011,2,20]],"date-time":"2011-02-20T09:31:24Z","timestamp":1298194284000},"page":"259-265","source":"Crossref","is-referenced-by-count":25,"title":["Prospects for the gene therapy of spinal muscular atrophy"],"prefix":"10.1016","volume":"17","author":[{"given":"Marco A.","family":"Passini","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seng H.","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.molmed.2011.01.002_bib0005","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/0092-8674(95)90460-3","article-title":"Identification and characterization of a spinal muscular atrophy-determining gene","volume":"80","author":"Lefebvre","year":"1995","journal-title":"Cell"},{"key":"10.1016\/j.molmed.2011.01.002_bib0010","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.nurx.2006.01.010","article-title":"Therapeutics development for spinal muscular atrophy","volume":"3","author":"Sumner","year":"2006","journal-title":"NeuroRx"},{"key":"10.1016\/j.molmed.2011.01.002_bib0015","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.nurt.2008.08.007","article-title":"Spinal muscular atrophy","volume":"5","author":"Oskoui","year":"2008","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.molmed.2011.01.002_bib0020","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.spen.2006.06.008","article-title":"Spinal muscular atrophy: from gene to therapy","volume":"13","author":"Wirth","year":"2006","journal-title":"Semin. Pediatr. Neurol."},{"key":"10.1016\/j.molmed.2011.01.002_bib0025","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/nrn2670","article-title":"Spinal muscular atrophy why do low levels of survival motor neuron protein make motor neurons sick?","volume":"10","author":"Burghes","year":"2009","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.molmed.2011.01.002_bib0030","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/S0092-8674(00)80368-2","article-title":"The SMN-SIP1 complex has an essential role in spliceosome snRNP biogenesis","volume":"90","author":"Fischer","year":"1997","journal-title":"Cell"},{"key":"10.1016\/j.molmed.2011.01.002_bib0035","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1126\/science.1074962","article-title":"Essential role for the SMN complex in the specificity of snRNP assembly","volume":"298","author":"Pellizzoni","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.molmed.2011.01.002_bib0040","doi-asserted-by":"crossref","first-page":"e921","DOI":"10.1371\/journal.pone.0000921","article-title":"Ribonucleoprotein assembly defects correlate with spinal muscular atrophy severity and preferentially affect a subset of splicesomal snRNPs","volume":"9","author":"Gabanella","year":"2007","journal-title":"PLoS ONE"},{"key":"10.1016\/j.molmed.2011.01.002_bib0045","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.1093\/hmg\/ddn156","article-title":"Reduced SMN protein impairs maturation of the neuromuscular junctions in mouse models of spinal muscular atrophy","volume":"17","author":"Kariya","year":"2008","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.molmed.2011.01.002_bib0050","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1083\/jcb.200703187","article-title":"Defective Ca2+ channel clustering in axon terminals disturbs excitability in motoneurons in spinal muscular atrophy","volume":"179","author":"Jablonka","year":"2007","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.molmed.2011.01.002_bib0055","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1523\/JNEUROSCI.4434-08.2009","article-title":"Impaired synaptic vesicle release and immaturity of neuromuscular junctions in spinal muscular atrophy mice","volume":"29","author":"Kong","year":"2009","journal-title":"J. Neurosci."},{"key":"10.1016\/j.molmed.2011.01.002_bib0060","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1083\/jcb.200303168","article-title":"Knockdown of the survival motor neuron (Smn) protein in zebrafish causes defects in motor axon outgrowth and pathfinding","volume":"162","author":"McWhorter","year":"2003","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.molmed.2011.01.002_bib0065","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1083\/jcb.200304128","article-title":"Smn, the spinal muscular atrophy-determining gene product, modulates axon growth and localization of beta-actin mRNA in growth cones of motoneurons","volume":"163","author":"Rossoll","year":"2003","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.molmed.2011.01.002_bib0070","doi-asserted-by":"crossref","first-page":"8622","DOI":"10.1523\/JNEUROSCI.3967-05.2006","article-title":"Multiprotein complexes of the survival of motor neuron protein SMN with Gemins traffic to neuronal processes and growth cones of motor neurons","volume":"26","author":"Zhang","year":"2006","journal-title":"J. Neurosci."},{"key":"10.1016\/j.molmed.2011.01.002_bib0075","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1126\/science.1155085","article-title":"Plastin 3 is a protective modifier of autosomal recessive spinal muscular atrophy","volume":"320","author":"Oprea","year":"2008","journal-title":"Science"},{"key":"10.1016\/j.molmed.2011.01.002_bib0080","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1172\/JCI29562","article-title":"Trichostatin A increases SMN expression and survival in a mouse model of spinal muscular atrophy","volume":"117","author":"Avila","year":"2007","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.molmed.2011.01.002_bib0085","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1002\/ana.21449","article-title":"Sustained improvement of spinal muscular atrophy mice treated with trichostatin A plus nutrition","volume":"64","author":"Narver","year":"2008","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.molmed.2011.01.002_bib0090","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1093\/hmg\/ddp510","article-title":"Effects of 2,4-diaminoquinazoline derivatives on SMN expression and phenotype in a mouse model for spinal muscular atrophy","volume":"19","author":"Butchbach","year":"2010","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.molmed.2011.01.002_bib0095","doi-asserted-by":"crossref","first-page":"3645","DOI":"10.1093\/hmg\/ddp313","article-title":"LBH589 induces up to 10-fold SMN protein levels by several independent mechanisms and is effective even in cells from SMA patients non-responsive to valproate","volume":"18","author":"Garbes","year":"2009","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.molmed.2011.01.002_bib0100","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1093\/hmg\/ddq023","article-title":"SAHA ameliorates the SMA phenotype in two mouse models for spinal muscular atrophy","volume":"19","author":"Riessland","year":"2010","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.molmed.2011.01.002_bib0105","doi-asserted-by":"crossref","first-page":"3906","DOI":"10.1093\/hmg\/ddp333","article-title":"Delivery of a read-through inducing compound, TC007, lessens the severity of a spinal muscular atrophy animal model","volume":"18","author":"Mattis","year":"2009","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.molmed.2011.01.002_bib0110","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1007\/s00109-008-0388-1","article-title":"Multiple therapeutic effects of valproic acid in spinal muscular atrophy model mice","volume":"86","author":"Tsai","year":"2008","journal-title":"J. Mol. Med."},{"key":"10.1016\/j.molmed.2011.01.002_bib0115","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3000208","article-title":"Tetracyclines that promote SMN2 exon 7 splicing as therapeutics for spinal muscular atrophy","volume":"1","author":"Hastings","year":"2009","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.molmed.2011.01.002_bib0120","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.nmd.2008.05.004","article-title":"Daily salbutamol in young patients with SMA type II","volume":"18","author":"Pane","year":"2008","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.molmed.2011.01.002_bib0125","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1007\/s11940-009-0012-x","article-title":"Emerging treatment options for spinal muscular atrophy","volume":"11","author":"Burnett","year":"2009","journal-title":"Curr. Treat. Options Neurol."},{"key":"10.1016\/j.molmed.2011.01.002_bib0130","doi-asserted-by":"crossref","first-page":"e12140","DOI":"10.1371\/journal.pone.0012140","article-title":"SMA CARNI-VAL trial part I: double-blind, randomized, placebo-controlled trial of L-carnitine and valproic acid in spinal muscular atrophy","volume":"5","author":"Swoboda","year":"2010","journal-title":"PLoS ONE"},{"key":"10.1016\/j.molmed.2011.01.002_bib0135","doi-asserted-by":"crossref","first-page":"e5268","DOI":"10.1371\/journal.pone.0005268","article-title":"Phase II open label study of valproic acid in spinal muscular atrophy","volume":"4","author":"Swoboda","year":"2009","journal-title":"PLoS ONE"},{"key":"10.1016\/j.molmed.2011.01.002_bib0140","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1212\/01.wnl.0000249142.82285.d6","article-title":"Randomized, double-blind, placebo-controlled trial of phenylbutyrate in spinal muscular atrophy","volume":"68","author":"Mercuri","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.molmed.2011.01.002_bib0145","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1002\/mus.20439","article-title":"Gene-based treatment of motor neuron diseases","volume":"33","author":"Federici","year":"2006","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.molmed.2011.01.002_bib0150","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.ymthe.2005.11.009","article-title":"Recombinant adeno-associated virus vectors as therapeutic agents to treat neurological disorders","volume":"13","author":"Mandel","year":"2006","journal-title":"Mol. Ther."},{"key":"10.1016\/j.molmed.2011.01.002_bib0155","doi-asserted-by":"crossref","first-page":"517","DOI":"10.4155\/tde.10.50","article-title":"Viral vectors and delivery strategies for CNS gene therapy","volume":"1","author":"Gray","year":"2010","journal-title":"Ther. Deliv."},{"key":"10.1016\/j.molmed.2011.01.002_bib0160","doi-asserted-by":"crossref","first-page":"428","DOI":"10.2174\/156652309789753383","article-title":"AAV as a gene transfer vector for the treatment of neurological disorders: novel treatment thoughts for ALS","volume":"9","author":"Hester","year":"2009","journal-title":"Curr. Gene Ther."},{"key":"10.1016\/j.molmed.2011.01.002_bib0165","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1002\/jgm.885","article-title":"Immune responses to AAV in a phase I study for Canavan disease","volume":"8","author":"McPhee","year":"2006","journal-title":"J. Gene Med."},{"key":"10.1016\/j.molmed.2011.01.002_bib0170","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1016\/S0140-6736(07)60982-9","article-title":"Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial","volume":"369","author":"Kaplitt","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.molmed.2011.01.002_bib0175","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1089\/hum.2008.022","article-title":"Treatment of late infantile neuronal ceroid lipofuscinosis by CNS administration of a serotype 2 adeno-associated virus expressing CLN2 cDNA","volume":"19","author":"Worgall","year":"2008","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.molmed.2011.01.002_bib0180","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/S1474-4422(08)70065-6","article-title":"Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial","volume":"7","author":"Marks","year":"2008","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.molmed.2011.01.002_bib0185","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1212\/01.wnl.0000312381.29287.ff","article-title":"Results from a phase I safety trial of hAADC gene therapy for Parkinson disease","volume":"70","author":"Eberling","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.molmed.2011.01.002_bib0190","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1212\/WNL.0b013e3181c29356","article-title":"Safety and tolerability of putaminal AADC gene therapy for Parkinson disease","volume":"73","author":"Christine","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.molmed.2011.01.002_bib0195","first-page":"240","article-title":"CERE-110, an adeno-associated virus-based gene delivery vector expressing human nerve growth factor for the treatment of Alzheimer's disease","volume":"12","author":"Mandel","year":"2010","journal-title":"Curr. Opin. Mol. Ther."},{"key":"10.1016\/j.molmed.2011.01.002_bib0200","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/mt.2009.277","article-title":"Gene therapy for Leber's congenital amaurosis is safe and effective through 1.5 years after vector administration","volume":"18","author":"Simonelli","year":"2010","journal-title":"Mol. Ther."},{"key":"10.1016\/j.molmed.2011.01.002_bib0205","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2165\/11533740-000000000-00000","article-title":"Gene therapy in Parkinson's disease: rationale and current status","volume":"24","author":"Feng","year":"2010","journal-title":"CNS Drugs"},{"key":"10.1016\/j.molmed.2011.01.002_bib0210","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1093\/hmg\/ddi078","article-title":"SMN\u03947, the major product of the centromeric survival motor neuron (SMN2) gene, extends survival in mice with spinal muscular atrophy and associates with full-length SMN","volume":"14","author":"Le","year":"2005","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.molmed.2011.01.002_bib0215","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1172\/JCI22922","article-title":"Lentivector-mediated SMN replacement in a mouse model of spinal muscular atrophy","volume":"114","author":"Azzouz","year":"2004","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.molmed.2011.01.002_bib0220","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1038\/mt.2008.87","article-title":"Safety and efficacy of regional intravenous versus intramuscular delivery of rAAV1 and rAAV8 to non-human primate skeletal muscle","volume":"16","author":"Toromanoff","year":"2008","journal-title":"Mol. Ther."},{"key":"10.1016\/j.molmed.2011.01.002_bib0225","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/gt.2009.119","article-title":"Efficient transduction of non-human primate motor neurons after intramuscular delivery of recombinant AAV serotype 6","volume":"17","author":"Towne","year":"2010","journal-title":"Gene Ther."},{"key":"10.1016\/j.molmed.2011.01.002_bib0230","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/nbt.1515","article-title":"Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes","volume":"27","author":"Foust","year":"2009","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.molmed.2011.01.002_bib0235","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/nbt.1610","article-title":"Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN","volume":"28","author":"Foust","year":"2010","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.molmed.2011.01.002_bib0240","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1038\/nbt0109-42","article-title":"Crossing the rubicon","volume":"27","author":"Lowenstein","year":"2009","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.molmed.2011.01.002_bib0245","doi-asserted-by":"crossref","first-page":"35ra42","DOI":"10.1126\/scitranslmed.3000830","article-title":"Systemic delivery of scAAV9 expressing SMN prolongs survival in a model of spinal muscular atrophy","volume":"2","author":"Valori","year":"2010","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.molmed.2011.01.002_bib0250","article-title":"Intravenous scAAV9 delivery of a codon-optimized SMN1 sequence rescues SMA mice","author":"Dominquez","year":"2010","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.molmed.2011.01.002_bib0255","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1172\/JCI41615","article-title":"CNS-targeted gene therapy improves survival and motor function in a mouse model of spinal muscular atrophy","volume":"120","author":"Passini","year":"2010","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.molmed.2011.01.002_bib0260","doi-asserted-by":"crossref","first-page":"3895","DOI":"10.1093\/hmg\/ddq300","article-title":"Early heart failure in the SMN Delta-7 model of spinal muscular atrophy and correction by postnatal scAAV9-SMN delivery","volume":"19","author":"Bevan","year":"2010","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.molmed.2011.01.002_bib0265","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1097\/PHM.0b013e31804b1d66","article-title":"Medical considerations of long-term survival of Werdnig-Hoffmann disease","volume":"86","author":"Bach","year":"2007","journal-title":"Am. J. Phys. Med. Rehabil."},{"key":"10.1016\/j.molmed.2011.01.002_bib0270","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1136\/jmg.2008.057950","article-title":"Congenital heart disease is a feature of severe infantile spinal muscular atrophy","volume":"45","author":"Rudnik-Sch\u00f6neborn","year":"2008","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.molmed.2011.01.002_bib0275","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.braindev.2005.02.009","article-title":"Autonomic dysfunction in cases of spinal muscular atrophy type 1 with long survival","volume":"27","author":"Hachiya","year":"2005","journal-title":"Brain Dev."},{"key":"10.1016\/j.molmed.2011.01.002_bib0280","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1002\/ajmg.a.32233","article-title":"Congenital heart defects in spinal muscular atrophy type I: a clinical report of two siblings and a review of the literature","volume":"146A","author":"Menke","year":"2008","journal-title":"Am. J. Med. Genet. A"},{"key":"10.1016\/j.molmed.2011.01.002_bib0285","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1093\/hmg\/ddg143","article-title":"Therapeutic benefits of cardiotrophin-1 gene transfer in a mouse model of spinal muscular atrophy","volume":"12","author":"Lesbordes","year":"2003","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.molmed.2011.01.002_bib0290","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1093\/hmg\/10.18.1925","article-title":"Protective effects of cardiotrophin-1 adenovirus gene transfer on neuromuscular degeneration in transgenic ALS mice","volume":"10","author":"Bordet","year":"2001","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.molmed.2011.01.002_bib0295","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1038\/mt.2010.206","article-title":"AAV4-mediated expression of IGF-1 and VEGF within cellular components of the ventricular system improves survival outcome in familial ALS mice","volume":"18","author":"Dodge","year":"2010","journal-title":"Mol. Ther."},{"key":"10.1016\/j.molmed.2011.01.002_bib0300","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1126\/science.1086137","article-title":"Retrograde viral delivery of IGF-1 prolongs survival in a mouse ALS model","volume":"301","author":"Kaspar","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.molmed.2011.01.002_bib0305","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/nature02544","article-title":"VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model","volume":"429","author":"Azzouz","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.molmed.2011.01.002_bib0310","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/hmg\/ddq147","article-title":"Spinal muscular atrophy: mechanism and therapeutic strategies","volume":"19","author":"Lorson","year":"2010","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.molmed.2011.01.002_bib0315","doi-asserted-by":"crossref","first-page":"e3468","DOI":"10.1371\/journal.pone.0003468","article-title":"Development of a single vector system that enhances trans-splicing of SMN2 transcripts","volume":"3","author":"Coady","year":"2008","journal-title":"PLoS ONE"},{"key":"10.1016\/j.molmed.2011.01.002_bib0320","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1523\/JNEUROSCI.4489-09.2010","article-title":"Trans-splicing-mediated improvement in a severe mouse model of spinal muscular atrophy","volume":"30","author":"Coady","year":"2010","journal-title":"J. Neurosci."},{"key":"10.1016\/j.molmed.2011.01.002_bib0325","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1089\/hum.2008.067","article-title":"A negatively acting bifunctional RNA increases survival motor neuron both in vitro and in vivo","volume":"19","author":"Dickson","year":"2008","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.molmed.2011.01.002_bib0330","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1093\/hmg\/ddp076","article-title":"Delivery of bifunctional RNAs that target an intronic repressor and increase SMN levels in an animal model of spinal muscular atrophy","volume":"18","author":"Baughan","year":"2009","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.molmed.2011.01.002_bib0335","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1038\/sj.mt.6300200","article-title":"Spinal muscular atrophy: SMN2 pre-mRNA splicing corrected by a U7 snRNA derivative carrying a splicing enhancer sequence","volume":"15","author":"Marquis","year":"2007","journal-title":"Mol. Ther."},{"key":"10.1016\/j.molmed.2011.01.002_bib0340","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1093\/hmg\/ddn382","article-title":"Rescue of a severe mouse model for spinal muscular atrophy by U7 snRNA-mediated splicing modulation","volume":"18","author":"Meyer","year":"2009","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.molmed.2011.01.002_bib0345","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1038\/mt.2009.71","article-title":"Intravenous administration of self-complementary AAV9 enables transgene delivery to adult motor neurons","volume":"17","author":"Duque","year":"2009","journal-title":"Mol. Ther."},{"key":"10.1016\/j.molmed.2011.01.002_bib0350","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1023\/A:1007049806660","article-title":"Osmotic opening of the blood-brain barrier: principles, mechanism, and therapeutic applications","volume":"20","author":"Rapoport","year":"2000","journal-title":"Cell. Mol. Neurobiol."},{"key":"10.1016\/j.molmed.2011.01.002_bib0355","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/1744-8069-6-31","article-title":"Differential adeno-associated virus mediated gene transfer to sensory neurons following intrathecal delivery by direct lumbar puncture","volume":"6","author":"Vulchanova","year":"2010","journal-title":"Mol. Pain"},{"key":"10.1016\/j.molmed.2011.01.002_bib0360","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1038\/sj.gt.3302961","article-title":"Significantly increased lifespan and improved behavioral performances by rAAV gene delivery in adult mucopolysaccharidosis IIIB mice","volume":"14","author":"Fu","year":"2007","journal-title":"Gene Ther."},{"key":"10.1016\/j.molmed.2011.01.002_bib0365","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/nm1358","article-title":"Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response","volume":"12","author":"Manno","year":"2006","journal-title":"Nat. Med."},{"key":"10.1016\/j.molmed.2011.01.002_bib0370","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1177\/0883073807305665","article-title":"Perspectives on clinical trials in spinal muscular atrophy","volume":"22","author":"Swoboda","year":"2007","journal-title":"J. Child Neurol."},{"key":"10.1016\/j.molmed.2011.01.002_bib0375","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1002\/ana.20473","article-title":"Natural history of denervation in SMA: relationship to age, SMN2 copy number, and function","volume":"57","author":"Swoboda","year":"2005","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.molmed.2011.01.002_bib0380","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s00415-005-0912-y","article-title":"SMN2 copy number predicts acute or chronic spinal muscular atrophy but does not account for intrafamilial variability in siblings","volume":"253","author":"Cusco","year":"2006","journal-title":"J. Neurol."},{"key":"10.1016\/j.molmed.2011.01.002_bib0385","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1097\/MOP.0b013e3282f1884c","article-title":"Clinical trials in spinal muscular atrophy","volume":"19","author":"Darras","year":"2007","journal-title":"Curr. Opin. Pediatr."},{"key":"10.1016\/j.molmed.2011.01.002_bib0390","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1177\/0883073807305670","article-title":"Modern management of spinal muscular atrophy","volume":"22","author":"Iannaccone","year":"2007","journal-title":"J. Child Neurol."},{"key":"10.1016\/j.molmed.2011.01.002_bib0395","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1212\/01.wnl.0000290830.40544.b9","article-title":"The changing natural history of spinal muscular atrophy type 1","volume":"69","author":"Oskoui","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.molmed.2011.01.002_bib0400","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1002\/mus.21838","article-title":"Compound muscle action potential and motor function in children with spinal muscular atrophy","volume":"42","author":"Lewelt","year":"2010","journal-title":"Muscle Nerve"}],"container-title":["Trends in Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471491411000037?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471491411000037?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,4]],"date-time":"2018-12-04T17:22:42Z","timestamp":1543944162000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1471491411000037"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,5]]},"references-count":80,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2011,5]]}},"alternative-id":["S1471491411000037"],"URL":"https:\/\/doi.org\/10.1016\/j.molmed.2011.01.002","relation":{},"ISSN":["1471-4914"],"issn-type":[{"value":"1471-4914","type":"print"}],"subject":[],"published":{"date-parts":[[2011,5]]}}}